Some new research papers indicate that Covid-19 survivors who have received the first dose of the Covid-19 vaccine are developing an immune response and may not need to be injected again, which may release a limited vaccine supply for more people.
Although this study is preliminary, it has been found that compared with people who have been vaccinated before but who are not sick, people who have been previously infected have quickly developed protection against the disease after the first shot of the current two-dose treatment regimen. And its level is greatly improved.
“Everyone should be vaccinated. Not everyone needs two shots.” said Viviana Simon, professor of microbiology at Icahn School of Medicine in New York at Mount Sinai, and author of a study. “As long as we can̵
This research has been published on the preprint server, but has not been peer-reviewed or published in a scientific journal. At the same time, other findings of the two-dose treatment regimen for healthy people in the general population also highlight the benefits of immunity after the first injection. On Friday, Israeli researchers reported a single injection of the vaccine from Pfizer, and BioNTech SE was effective in preventing symptomatic diseases 15 to 28 days after vaccination at 85%.
Late-stage clinical trials of the two-dose vaccine conducted by Pfizer, BioNTech and Moderna Inc. have shown that their injections are safe and highly protective against Covid-19 when injected with two doses of the vaccine several weeks apart. However, Pfizer’s trial ruled out people with Covid-19 symptoms, while Moderna ruled out people with previously known infections, prompting researchers to understand how the immune systems of previously ill people respond.